Exicure's Series B - II Round

Exicure raised a round of funding on July 31, 2013.

Exicure, formerly AuraSense Therapeutics, is developing a new class of immunomodulatory and gene silencing drugs against validated targets. The company's 3-dimensional, spherical nucleic acid (SNA) ar…

Articles about Exicure's Series B - II Round: